PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

European Journal of Clinical Pharmacology

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

European Journal of Clinical Pharmacology has 1 tracked paper indexed in Blossom (2021) from 3 authors, most often covering Ketamine and Esketamine, across Depressive Disorders, Suicidality and Safety & Risk Management.

Published Papers

Open Accessmeta

Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses

This review (2021) summarizes the current state of research regarding the use of ketamine and esketamine for depression. Across 11 studies it was found that ketamine alleviated symptoms of depression 40 min to 1 week while esketamine improved symptoms at 2 hours to 4 weeks. The methodological quality of most reviews was described as critically low.

Published
October 27, 2021
Journal
European Journal of Clinical Pharmacology
Authors
de Mendoça Lima, T., Visacri, M. B., Aguiar, P. M.

Quick Facts

Papers Indexed
1
h-Index
126
Open Access
No
Publisher
Springer Nature
Country
Germany
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.